This article first appeared on GuruFocus. Profound Medical Corp (NASDAQ:PROF) is set to release its Q1 2026 earnings on May 7, 2026. The consensus estimate for Q1 2026 revenue is $4.85 million, and ...

Profound Medical (PROF) delivered earnings and revenue surprises of +21.91% and +4.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Are they profound wisdom? Or are they bull? If you thought they were profound, you might need your BS detector checked. Created from the website wisdomofchopra.com, this “wisdom” was generated by ...

61% were treated for prostate cancer only, 28% were hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”), 10% were salvage, and 1% were men with BPH only; For ...

CEO Arun Menawat highlighted the CAPTAIN trial results presented at the American Urological Association Meeting, describing them as establishing TULSA's statistical superiority over robotic radical ...

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

Good afternoon, ladies and gentlemen, and welcome to the Profound Medical Q1 2026 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Thursday, May 7, 2026. I ...

CEO Arun Swarup Menawat summarized that "our sales team has been stabilized. That, combined with our large and growing TULSA-PRO pipeline, continues to drive our confidence in our ability to deliver ...

The Kansas City–based firm is now listed in Profound’s official partner directory as the most AEO-certified consultancy globally, marking a major step forward in how influence is built and measured in ...

With a new report, the Centers for Disease Control and Prevention is tacitly embracing a recently coined autism classification and providing a first-of-its-kind breakdown on the number of kids on the ...